

Heather H Cheng

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3048978/heather-h-cheng-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

78
papers

6,604
citations

25
h-index

81
g-index

85
ext. papers

8,492
ext. citations

6.9
avg, IF

5.57
L-index

#	Paper	IF	Citations
78	Operationalizing Genetic Testing in the Care of Patients with Prostate Cancer 2022 , 61-73		
77	Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.. <i>Lancet Oncology, The</i> , 2022 ,	21.7	7
76	A Patient-Centered Approach to Research Prioritization in Prostate Cancer.. <i>Journal of Urology</i> , 2022 , 101097JU0000000000002694	2.5	
75	Germline genetics of prostate cancer. <i>Prostate</i> , 2022 , 82,	4.2	1
74	Germline Testing in Prostate Cancer: When and Who to Test. <i>Oncology</i> , 2021 , 35, 645-653	1.8	1
73	Inherited TP53 Variants and Risk of Prostate Cancer. <i>European Urology</i> , 2021 ,	10.2	4
72	Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. <i>Prostate</i> , 2021 , 81, 433-439	4.2	8
71	Barriers and facilitators of germline genetic evaluation for prostate cancer. <i>Prostate</i> , 2021 , 81, 754-764	4.2	2
70	CD38 in Advanced Prostate Cancers. <i>European Urology</i> , 2021 , 79, 736-746	10.2	0
69	Differential Activity of PARP Inhibitors in - Versus -Altered Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	2
68	Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 144-154	3.3	1
67	Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference. <i>JAMA Oncology</i> , 2021 , 7, 107-110	13.4	34
66	NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021 , 19, 134-143	7.3	71
65	Genetic Contribution to Metastatic Prostate Cancer. <i>Urologic Clinics of North America</i> , 2021 , 48, 349-363	2.9	
64	Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 6001-6011	12.9	0
63	Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 496.e1-496.e8	2.8	0
62	Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations. <i>Prostate</i> , 2021 , 81, 1382-1389	4.2	1

61	Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies. <i>PLoS ONE</i> , 2020 , 15, e0233260	3.7	29
60	Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2407-2417	2.2	44
59	CD8 T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens. <i>Molecular Therapy</i> , 2020 , 28, 1238-1250	11.7	7
58	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2798-2811	2.2	80
57	Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020 , 23, 486-493	6.2	2
56	Genetic Testing in Prostate Cancer. <i>Current Oncology Reports</i> , 2020 , 22, 5	6.3	10
55	Complexities of Next-Generation Sequencing in Solid Tumors: Case Studies. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 1150-1155	7.3	3
54	Implementation of systematic germline genetic testing (GT) for metastatic prostate cancer (mPC) patients at the Puget Sound VA prostate oncology clinic.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1578-1578	2.2	1
53	Ethnic disparities among men with prostate cancer undergoing germline testing. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 80.e1-80.e7	2.8	19
52	Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 83-93	2.8	8
51	Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. <i>JCO Oncology Practice</i> , 2020 , 16, 811-819	2.3	16
50	Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes. <i>Bladder Cancer</i> , 2020 , 6, 71-81	1	8
49	Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer. <i>PLoS ONE</i> , 2020 , 15, e0239686	3.7	4
48	Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3740-3742	2.2	9
47	Honing in on PARPi Response in Prostate Cancer: from HR Pathway to Gene-by-Gene Granularity. <i>Clinical Cancer Research</i> , 2020 , 26, 2439-2440	12.9	8
46	Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 275-282.e1	3.3	22
45	Clinical determinants for successful circulating tumor DNA analysis in prostate cancer. <i>Prostate</i> , 2019 , 79, 701-708	4.2	9
44	Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. <i>European Urology</i> , 2019 , 76, 452-458	10.2	69

43	Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy. <i>JCI Insight</i> , 2019 , 5,	9.9	14
42	Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. <i>Journal of Clinical Investigation</i> , 2019 , 129, 4492-4505	15.9	102
41	Germline and Somatic Mutations in Prostate Cancer for the Clinician. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 515-521	7.3	42
40	Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 352.e19-352.e24	2.8	
39	Bladder Cancer Multidisciplinary Clinic (BCMC) Model Influences Disease Assessment and Impacts Treatment Recommendations. <i>Bladder Cancer</i> , 2019 , 5, 289-298	1	4
38	Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	21
37	Hepatitis C infection and chemotherapy toxicity. <i>Journal of Oncology Pharmacy Practice</i> , 2019 , 25, 474-480		3
36	Germline contributions to metastatic prostate cancer. <i>Canadian Journal of Urology</i> , 2019 , 26, 19-21	0.8	2
35	Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. <i>European Urology</i> , 2018 , 73, 687-693	10.2	70
34	The resounding effect of DNA repair deficiency in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 385-388	2.8	6
33	A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. <i>PLoS ONE</i> , 2018 , 13, e0198389	3.7	51
32	Undetectable prostate-specific antigen after short-course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis-free survival and prostate cancer-specific survival. <i>Prostate</i> , 2018 , 78, 1077	4.2	
31	Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. <i>Prostate</i> , 2018 , 78, 121-127	4.2	15
30	Practical Methods for Integrating Genetic Testing Into Clinical Practice for Advanced Prostate Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018 , 38, 372-381	7.1	15
29	Polyclonal Reversion Mutations Detected in Circulating Tumor DNA After Platinum Chemotherapy in a Patient With Metastatic Prostate Cancer. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6	8
28	Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. <i>JCO Precision Oncology</i> , 2018 , 2018,	3.6	10
27	Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2017 , 77, 1478-1488	4.2	2
26	Prostate Cancer Screening in a New Era of Genetics. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 625-628	3.3	19

25	Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017 , 26, 222-227	4	26
24	Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer. <i>Medical Oncology</i> , 2016 , 33, 77	3.7	8
23	Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016 , 69, 992-5	10.2	175
22	Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate. <i>Oncotarget</i> , 2016 , 7, 82504-82510	3.3	47
21	A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling. <i>Prostate</i> , 2016 , 76, 1303-11	4.2	14
20	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 443-53	59.2	791
19	SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1601-8	2.2	38
18	Improved disease markers suggest dual response in a patient with metastatic castration resistant prostate cancer and chronic lymphocytic leukemia following active cellular immunotherapy. <i>Journal of Hematology and Oncology</i> , 2015 , 8, 51	22.4	2
17	Integrative clinical genomics of advanced prostate cancer. <i>Cell</i> , 2015 , 161, 1215-1228	56.2	1765
16	Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. <i>Prostate Cancer and Prostatic Diseases</i> , 2015 , 18, 122-7	6.2	63
15	Long-term survival in bone-predominant metastatic urothelial carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, e241-4	3.3	4
14	Quantitative and stoichiometric analysis of the microRNA content of exosomes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 14888-93	11.5	676
13	Role of maximal endoscopic resection before cystectomy for invasive urothelial bladder cancer. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 287-91	3.3	16
12	Nonresponse to neoadjuvant chemotherapy for muscle-invasive urothelial cell carcinoma of the bladder. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 210-3	3.3	6
11	Glucocorticoids and prostate cancer treatment: friend or foe?. <i>Asian Journal of Andrology</i> , 2014 , 16, 354-8.8		29
10	Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer. <i>Advances in Urology</i> , 2013 , 2013, 317-190	1.6	23
9	Plasma processing conditions substantially influence circulating microRNA biomarker levels. <i>PLoS ONE</i> , 2013 , 8, e64795	3.7	217
8	Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. <i>PLoS ONE</i> , 2013 , 8, e69239	3.7	124

7	Advanced clinical states in prostate cancer. <i>Urologic Clinics of North America</i> , 2012 , 39, 561-71	2.9	15
6	MicroRNA profiling: approaches and considerations. <i>Nature Reviews Genetics</i> , 2012 , 13, 358-69	30.1	1185
5	Feline leukemia virus T entry is dependent on both expression levels and specific interactions between cofactor and receptor. <i>Virology</i> , 2007 , 359, 170-8	3.6	7
4	Envelope determinants for dual-receptor specificity in feline leukemia virus subgroup A and T variants. <i>Journal of Virology</i> , 2006 , 80, 1619-28	6.6	9
3	Envelope Determinants for Dual-Receptor Specificity in Feline Leukemia Virus Subgroup A and T Variants. <i>Journal of Virology</i> , 2006 , 80, 12431-12431	6.6	78
2	Genetic and biochemical analyses of receptor and cofactor determinants for T-cell-tropic feline leukemia virus infection. <i>Journal of Virology</i> , 2002 , 76, 8069-78	6.6	15
1	lazarus is a novel pbx gene that globally mediates hox gene function in zebrafish. <i>Molecular Cell</i> , 2000 , 6, 255-67	17.6	126